InvestSMART

Racura Oncology Ltd (ASX: RAC) - Share Price

- Current share price for RAC : $1.480

Racura Oncology (RAC) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a Phase 3 clinical biopharmaceutical company with a mission to be at the heart of cancer care.

RAC General Information +

ASX Code RAC
Website N/A
Industry/Sector Biotechnology
Market Cap ($M) 290
RAC Share Price $1.480
Day High $1.495
Day Low $1.400
Last Close $1.480
RAC Share Price Movement - ( No change )
Prices as at 16:40, 5 Nov 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Racura Oncology Ltd (RAC) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Racura Oncology Ltd (RAC) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Racura Oncology Ltd (RAC) price-sensitive announcements

RAC - Sept 2026 Quarterly Activities Report and Appendix 4C
Racura Oncology Ltd’s September 2026 Quarterly Activities Report and Appendix 4C for Q1 FY
Racura Oncology Ltd (RAC)
22 Oct 2026 | 9:52 AM
RAC - HARNESS-1 First Cohort Cleared
Racura Oncology Ltd (ASX: RAC) announced that the HARNESS-1 Safety Review Committee cleare
Racura Oncology Ltd (RAC)
12 Oct 2026 | 8:51 AM
RAC - CPACS Trial Opens for RC220 Patient Enrolment in Korea
Racura Oncology Ltd (ASX: RAC) announced that the CPACS Phase 1 trial of RC220 in combinat
Racura Oncology Ltd (RAC)
1 Sep 2026 | 8:58 AM
RAC - Appendix 4E & Annual Report
Racura Oncology Ltd, formerly known as Race Oncology Limited, reported significant advance
Racura Oncology Ltd (RAC)
25 Aug 2026 | 5:21 PM

Racura Oncology Ltd (RAC) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Racura Oncology Ltd (RAC)
ORDINARY FULLY PAID
Health Care $290 Letter to Shareholders, Notice of AGM & Proxy Form 22 Oct 2026 1:46PM $1.555 $1.480 fallen by 4.82%
Racura Oncology Ltd (RAC)
ORDINARY FULLY PAID
Health Care $290 Sept 2026 Quarterly Activities Report and Appendix 4C 22 Oct 2026 9:52AM $1.560 $1.480 fallen by 5.13%
Racura Oncology Ltd (RAC)
ORDINARY FULLY PAID
Health Care $290 HARNESS-1 First Cohort Cleared 12 Oct 2026 8:51AM $1.815 $1.480 fallen by 18.46%
Racura Oncology Ltd (RAC)
ORDINARY FULLY PAID
Health Care $290 Racura Presents CPACS Data at GCOS 2026 7 Oct 2026 8:54AM $1.855 $1.480 fallen by 20.22%
Racura Oncology Ltd (RAC)
ORDINARY FULLY PAID
Health Care $290 Date of AGM & Closing Date for Director Nominations 5 Oct 2026 8:36AM $1.920 $1.480 fallen by 22.92%
Racura Oncology Ltd (RAC)
ORDINARY FULLY PAID
Health Care $290 Appendix 3Y - Dr Daniel Tillett 29 Sep 2026 5:24PM $1.935 $1.480 fallen by 23.51%

RAC Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$9.95 -$5.60 99.60% 0.00 0.00 0.00% 0.0%
2025A -$4.79 -$2.80 -66.90% 0.00 0.00 0.00% 0.0%
2024A -$13.82 -$8.40 36.10% 0.00 0.00 0.00% 0.0%

RAC Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
CSL Limited (CSL) $94,700M 0.7309 -0.4400 0.0602 12.2256 21.8304 20.5912 2.15% 2.16% 2.23%
Mesoblast Limited (MSB) $2,733M -0.4501 0.0000 0.0000 0.0000 0.0000 954.5455 0.00% 0.00% 0.00%
PYC Therapeutics Limited (PYC) $1,822M -0.3971 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Racura Oncology Ltd (RAC) $274M 0.9964 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $4,533M -1.3893 0.0000 -0.5230 0.0000 156.8905 328.8889 0.00% 0.00% 0.00%

RAC Directors

Name Position Start Date
Dr Daniel Tillett Chief Executive Officer, Managing Director 1 Sep 2024
Dr Peter (Pete) Smith Executive Director, Executive Chairman 28 Jun 2023
Dr Megan Baldwin Non-Executive Director 1 Jan 2025
Dr Serge Scrofani Non-Executive Director 1 Sep 2024

Racura Oncology Ltd (RAC) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
25 Sep 2026 TILLETT, Daniel Buy Indirect Shares 23,000 $1.987 $45,701.550
22 Sep 2026 TILLETT, Daniel Buy Indirect Shares 80,000 $2.038 $163,040.000
22 Sep 2026 TILLETT, Daniel Buy Direct Shares 4,500 $2.038 $9,171.000

See all changes in directors' interest & trades for Racura Oncology Ltd (RAC) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

RAC Management

Name Position
Peter Webse Company Secretary

RAC Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Racura Oncology Ltd (RAC). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
20,269,351 (10.34%) Daniel Tillett

RAC Calendar of Events

Date Event
24 August 2027 Report (Annual)
24 August 2027 Report (Prelim)
26 February 2027 Report (Interim)
23 November 2026 AGM

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.